Paperpal Prime Logo

PharmacoEconomics - Open : Impact Factor & More

eISSN: 2509-4254pISSN: 2509-4262
JournalOpen Access

Key Metrics

CiteScore
2.9
H-Index
17
SJR
Q2Pharmacology
SNIP
0.78
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on PharmacoEconomics - Open

PharmacoEconomics - Open Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SPRINGER INT PUBL AG
Language English
Frequency Quarterly
Article Processing ChargesEUR 2790 | USD 3490 | GBP 2390
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2017
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in PharmacoEconomics - Open ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in PharmacoEconomics - Open

Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.
  • 1 Jul 2026
  • PharmacoEconomics - open
Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.
  • 29 Jun 2026
  • PharmacoEconomics - open
Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model.
  • 29 Jun 2026
  • PharmacoEconomics - open
Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer.
  • 18 Jun 2026
  • PharmacoEconomics - open
Health Utility Values Measured by EQ-5D in Breast Cancer From Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis Protocol.
  • 10 Jun 2026
  • PharmacoEconomics - open
Budget Impact Analysis of Vacuum-Assisted Excision Versus Surgical Excision for the Assessment of Breast Lesions of Uncertain Malignant Potential in Italy.
  • 9 Jun 2026
  • PharmacoEconomics - open
Cost-Effectiveness of Tezepelumab Versus Omalizumab in Patients with Severe Uncontrolled Allergic Asthma in Spain.
  • 1 Jul 2026
  • PharmacoEconomics - open
Availability, Prices, and Affordability of Immune Checkpoint Inhibitors: A Cross-Sectional Study in Anhui Province, China.
  • 29 Jun 2026
  • PharmacoEconomics - open
Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model.
  • 29 Jun 2026
  • PharmacoEconomics - open
Integrating Structured Expert Elicitation with External Evidence to Inform Earlier Reimbursement Decisions: A Norwegian Case Study of Selpercatinib for Non-Small Cell Lung Cancer.
  • 18 Jun 2026
  • PharmacoEconomics - open
Health Utility Values Measured by EQ-5D in Breast Cancer From Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis Protocol.
  • 10 Jun 2026
  • PharmacoEconomics - open
Budget Impact Analysis of Vacuum-Assisted Excision Versus Surgical Excision for the Assessment of Breast Lesions of Uncertain Malignant Potential in Italy.
  • 9 Jun 2026
  • PharmacoEconomics - open

FAQs on PharmacoEconomics - Open